Tevogen Bio (NASDAQ:TVGN) Posts Quarterly Earnings Results, Beats Estimates By $0.39 EPS

Tevogen Bio (NASDAQ:TVGN) announced its earnings results on Friday. The company reported ($1.61) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.00) by $0.39, FiscalAI reports.

Tevogen Bio Trading Down 15.6%

NASDAQ:TVGN traded down $1.47 during trading hours on Friday, reaching $7.95. 20,555 shares of the company traded hands, compared to its average volume of 27,610. The business’s 50-day moving average price is $6.33 and its two-hundred day moving average price is $14.49. The stock has a market capitalization of $33.07 million, a P/E ratio of -0.84 and a beta of 0.09. Tevogen Bio has a 1 year low of $4.14 and a 1 year high of $75.50.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Tevogen Bio in a report on Monday, April 20th. Wall Street Zen downgraded Tevogen Bio to a “strong sell” rating in a report on Saturday, March 21st. Finally, D. Boral Capital downgraded Tevogen Bio from a “buy” rating to a “hold” rating in a report on Wednesday, March 4th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Reduce” and an average target price of $100.00.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in TVGN. Bridgeway Capital Management LLC raised its stake in Tevogen Bio by 66.7% during the third quarter. Bridgeway Capital Management LLC now owns 82,500 shares of the company’s stock valued at $65,000 after buying an additional 33,000 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Tevogen Bio by 126.0% in the fourth quarter. Goldman Sachs Group Inc. now owns 273,694 shares of the company’s stock worth $91,000 after purchasing an additional 152,572 shares during the last quarter. Finally, Deutsche Bank AG raised its stake in shares of Tevogen Bio by 304.1% in the fourth quarter. Deutsche Bank AG now owns 173,734 shares of the company’s stock worth $57,000 after purchasing an additional 130,738 shares during the last quarter.

Tevogen Bio Company Profile

Tevogen Bio plc (NASDAQ:TVGN) is a clinical-stage biotechnology company focused on developing personalized natural killer (NK) cell immunotherapies for oncology and severe viral diseases. Leveraging proprietary induced pluripotent stem cell (iPSC) and donor-derived NK cell platforms, Tevogen Bio aims to create off-the-shelf cell therapy products that offer scalable and cost-efficient treatment options. The company’s lead candidate, TVGN-484, is an allogeneic NK cell therapy in clinical trials for relapsed or refractory acute myeloid leukemia (AML).

In addition to its lead program in AML, Tevogen Bio’s pipeline includes preclinical NK cell candidates directed against hematological malignancies, solid tumors and viral infections.